Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusion, RC220. The company has signed contracts with Attentive Science (USA) and Agilex Biolabs (Australia) to complete a package of Good Laboratory Practice (GLP) toxicology and safety pharmacology studies. Set to commence immediately, final reporting is expected mid next year.
Race Oncology kicks off safety studies for RC220
